SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused ...

(RTTNews) - RAPT Therapeutics, Inc. (RAPT) said it is terminating zelnecirnon program. Zelnecirnon was being evaluated in two randomized, placebo-controlled Phase 2 clinical trials in asthma and ...

Snowdonia could remove its English name from the national park’s logo after it said that using its Welsh name had been a success. Snowdonia National Park Authority voted to replace Snowdon with ...

RAPT Therapeutics has called it quits on a clinical programme evaluating zelnecirnon (RPT193) in inflammatory disorders following feedback with the US Food and Drug Administration (FDA).

Given this risk, we thought we'd take a look at whether RAPT Therapeutics (NASDAQ:RAPT) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn ...

Shares of RAPT Therapeutics (NASDAQ:RAPT) plunged 46% in early trading Monday after the company said it was scrapping development of its drug candidate zelnecirnon due to negative FDA feedback.

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a biotechnology company focused on developing small-molecule drugs for inflammatory diseases and cancer, has recently faced significant challenges in its drug ...

On Monday, JPMorgan (NYSE:JPM) issued a downgrade for Rapt Therapeutics (NASDAQ:RAPT), adjusting the stock's rating from Neutral to Underweight. The firm cited a lack of near-term value-creating ...

Rapt Therapeutics said Monday it would stop developing its one of its lead drug candidates after a patient had a reaction that required a liver transplant. The South San Francisco, Calif ...

Rapt pointed out again today that no cases of liver toxicity or any other treatment-related serious adverse event were reported in any participants from the phase 2b study of zelnecirnon.

RAPT Therapeutics to advance CCR4 compounds for inflammatory disease and expects to identify a new candidate in 1H 2025. RAPT Therapeutics laid off 47 people in July, or approximately 40% of the ...